Gene editing is changing the world. Founded by pioneers in the CRISPR/CAS revolution, Metagenomi is discovering the next generation of gene-editing systems for use in treating genetic diseases.Founded in 2018 by lead metagenomics researchers at UC Berkeley, Brian C. Thomas and Jillian Banfield, Metagenomi is committed to changing the landscape of cell and gene therapies. By using metagenomics to unlock 4 billion years of microbial evolution, Metagenomi is rapidly identifying and characterizing novel nucleases with unique gene editing capabilities. Metagenomi is using this expanded gene editing toolbox to develop game-changing in vivo and ex vivo therapeutics.
Total Funding: $65,000,000
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2018
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Metagenomi
